Search
Displaying 291–300 of 651 for “retinal diseases”
-
Foundation Fighting Blindness Comments on Proposed NIH Reforms
Foundation NewsThe Foundation responds to the U.S. House of Representatives Energy and Commerce Committee on the framework for reforming the National Institutes of Health
-
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Research NewsThe AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Brint Family Translational Research Award
The Brint Family Translational Research Program awards will accelerate the movement of preclinical research toward an Investigational New Drug filing and into clinical trials to provide a robust and diverse pipeline of potential therapies to fight inherited retinal degenerations (IRD) and dry age-related macular degeneration.
-
Nobel-Prize-Winning Stem-Cell Researcher Delivers Keynote at FFB-Funded Conference in Kyoto
Research NewsDr. Shinya Yamanka discussed his early clinical trial for iPSC-derived retinal pigment epithelial (RPE) cells for a 78-year-old woman with advanced wet age-related macular degeneration (AMD).
-
VISIONS 2015 — Dr. Shannon Boye Receives FFB Award for Excellence in Gene-Therapy Research
Research NewsDr. Boye received the Foundation’s Board of Director’s Award, which was presented at VISIONS 2015, FFB’s annual conference, for achievements in retinal research.
-
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
Research NewsThe XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
Research NewsThe company plans to administer a higher dose of the emerging gene therapy to the next group of patients.
-
Research News
Geographic atrophy (GA) is the advanced form of dry age-related macular degeneration (AMD) which causes blindness in one million people in the United States and 5 million worldwide.
This is the first time that a treatment has been approved for this leading cause of blindness.
